

TOM DAVIS, VIRGINIA,
CHAIRMAN

CHRISTOPHER SHAYS, CONNECTICUT
DAN BURTON, INDIANA
ILEANA ROS-LEHTINEN, FLORIDA
JOHN M. McHUGH, NEW YORK
JOHN L. MICA, FLORIDA
GIL GUTKNECHT, MINNESOTA
MARK E. SOUDER, INDIANA
STEVEN C. LATOURETTE, OHIO
TODD RUSSELL PLATTS, PENNSYLVANIA
CHRIS CANNON, UTAH
JOHN J. DUNCAN, JR., TENNESSEE
CANDICE MILLER, MICHIGAN
MICHAEL R. TURNER, OHIO
DARRELL ISSA, CALIFORNIA
VIRGINIA BROWN-WAITE, FLORIDA
JON C. PORTER, NEVADA
KENNY MARCHANT, TEXAS
LYNN A. WESTMORELAND, GEORGIA
PATRICK T. McHENRY, NORTH CAROLINA
CHARLES W. DENT, PENNSYLVANIA
VIRGINIA FOXX, NORTH CAROLINA

ONE HUNDRED NINTH CONGRESS

Congress of the United States

House of Representatives

COMMITTEE ON GOVERNMENT REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074
FACSIMILE (202) 225-3974
MINORITY (202) 225-5051
TTY (202) 225-6852

<http://reform.house.gov>

HENRY A. WAXMAN, CALIFORNIA,
RANKING MINORITY MEMBER

TOM LANTOS, CALIFORNIA
MAJOR R. OWENS, NEW YORK
EDOLPHUS TOWNS, NEW YORK
PAUL E. KANJORSKI, PENNSYLVANIA
CAROLYN B. MALONEY, NEW YORK
ELIJAH E. CUMMINGS, MARYLAND
DENNIS J. KUCINICH, OHIO
DANNY K. DAVIS, ILLINOIS
Wm. LACY CLAY, MISSOURI
DIANE E. WATSON, CALIFORNIA
STEPHEN F. LYNCH, MASSACHUSETTS
CHRIS VAN HOLLEN, MARYLAND
LINDA T. SANCHEZ, CALIFORNIA
C. A. DUTCH RUPPERSBERGER,
MARYLAND
BRIAN HIGGINS, NEW YORK
ELEANOR HOLMES NORTON,
DISTRICT OF COLUMBIA

BERNARD SANDERS, VERMONT,
INDEPENDENT

May 16, 2005

Mr. Paul Tagliabue
Commissioner
National Football League
280 Park Avenue
New York, New York 10017

Dear Mr. Tagliabue:

Thank you for participation at the Committee on Government Reform's April 27 hearing regarding the National Football League's (NFL) performance-enhancing drug testing policy. We particularly commend you for the steps you and Mr. Upshaw announced to strengthen the NFL's steroid testing policy.

We are writing today to request additional information from the NFL on the league's steroid testing program. At the hearing, the NFL announced changes to its performance-enhancing drug policy, including several that would make prohibitions against players taking testosterone more stringent. As a result of these changes, we are requesting additional information on the results of testosterone testing conducted by the NFL in recent years. Specifically, we ask that you provide, in electronic format, all analytical results since January 1, 1995, of the testing of testosterone and epitestosterone in all NFL players. Please include actual analytical results, i.e., urinary concentrations, for both testosterone and epitestosterone, not simply T:E ratios. In addition, please identify all tests that were conducted using Isotope Ratio Mass Spectrometry or any other data that was used to assess possible testosterone doping offenses prior to the introduction of Isotope Ratio Mass Spectrometry.

We are not seeking the names of individual players, but we do ask that you provide the data so that players can be tracked from year to year (by using, for example, a numeric code) without identifying the player in question. We are happy to work with you and your staff to ensure that the data is provided in the most useful format. If you have any questions regarding this letter, please contact Anne Marie Turner, Majority Counsel at (202) 225-5074 and Brian Cohen, Minority Professional Staff at (202) 225-5051.

Sincerely,



Tom Davis
Chairman



Henry A. Waxman
Ranking Minority Member